Clinical review of 55 cases of malignant ovarian germ cell tumors

Purpose of investigation: A retrospective analysis of 55 cases of malignant germ cell tumors in a 20-year period was done to evaluate the impact of conservative surgery and adjuvant treatment on survival and fertility.

Methods: Fifty-five cases of malignant ovarian germ cell tumors (MOGCTs) were studied. Mean age was 22 years. Dysgerminoma was the most common histotype (45%).

Results: Thirty-nine patients (71%) presented with FIGO surgical Stage I disease. Fertility-sparing surgery was performed in 39 (71%) women. Postoperative systemic chemotherapy was administered to 40 women (73%), 27 (68%) had received conservative treatment. One woman developed renal failure after the first cycle of chemotherapy and died a few days thereafter and there was one case of bleomycin-induced death due to pulmonary fibrosis. There were eight (14.5%) clinical recurrences. Overall survival rate for relapsing women was 75% (6/8). The recurrence rate for women treated conservatively was 15%, and it was 13% for those treated radically. With a median follow-up of 129 months the overall survival rate for the entire study-population was 90.9%. Eleven pregnancies occurred in 36 women treated with fertility-sparing surgery who were of child-bearing age.

Conclusion: The management of MOGCTs with fertility-sparing surgery is a safe, practicable treatment option. The majority of these patients can retain normal ovarian function and reproductive potential after chemotherapy treatment.

Malignant germ cell tumors; Dysgerminoma; Surgical treatment; Chemotherapy; Fertility

[1] Talerman A.: "Germ cell tumors of the ovary". In: Blaunstein's Pathology of the Female Genital Tract. Kurman J.K., New York, Springer 2002, 967.

[2] Di Saia P., Cresman W.T.: "Clinical Gynaecological Oncology". 5th ed. Mosby, 1997, 351.

[3] Williams S.D.: "Ovarian germ cell tumors: an update". Semm Oneal., 1998, 25 (3), 407.

[4] Serov S.F., Scully R.E., Sobin L.J.: "Histological typing of ovanan tumors". In: World Health Organization. International histological classification of tumors. Geneva: World Health Organization, 1973.

[5] Gershenson D.M.: "Update on malignant ovarian germ cell tumors". Cancer, 1993, S71 (4), 1581.

[6] Thurlbeck W.M., Scully R.E.: "Solid teratoma of the ovary: A clinicopathological analysis of 9 cases". Cancer, 1960, 13, 804.

[7] Norris H.J., Zirkin H.J., Benson W.L.: "Immature (malignant) teratoma of the ovary: A clinical and pathologic study of 58 cases" Cancer, 1976, 37, 2359.

[8] Serov S.F., Scully R.E., Robin L.H.: "International histological classification of tumors". Histological Typing of Tumors, WHO, Geneva, 1973.

[9] Zanetta G., Bonazzi C., Cantu M.G., Bini S., Locatelli A., Bratma G. et al.: "Survival ad reproductive function after treatment of malignant genn cell ovarian tumors". J. Clin. Oncol., 2001, 19 (4), 1015.

[10] Kunnan R.J., Norris H.J.: "Malignant mixed germ cell tumors of the ovary. A clinical and pathologic analysis of 30 cases". Obstet. Gynecol., 1976, 48,579.

[11] Gordon A., Lipton D., Woodruff J.D.: "Dysgermmoma: a review of 158 cases from the Emil Novak ovarian tumor registry". Obstet. Gynecol., 1981, 58, 497.

[12] Mueller C.W., Topkins P., Lapp W.A.: "Dysgerminoma of the ovary: an analysis of 427 cases". Am. J. Ohstet. Gynecol., 1984, 64,200

[13] Schwartz P.E., Chambers S.K., Chamber J.T., Kohorn E., Mclntosh S.: "Ovarian germ cell malignancies: the Yale University experience". Gynecol. Oncol., 1992, 45, 26.

[14] Gershenson D.M., Morris M., Cangir A., Kavanagh J.J., Stnnger C.A., Edwards C.L.: "Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide and cisplatin". J. Clin Oncol.,1 990, 8, 715.

[15] Brewer M., Gershenson D.M., Herzog C.E., Fallen Mitchell M., Silva E.G., Whartan J.T.: "Outcome and reproductive function after chemotherapy for ovarian dysgerminoma". J. Clin. Oneal., 1999, 17 (9), 2670.

[16] Low J.J.H., Perrin L.C., Crandon A.J., Hacker N.F.: "Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases". Cancer, 2000, 89 (2), 391.

[17] Gershenson D.M., Copeland L.J., Kavanagh J.J., Cangir A., Junco G.D., Saul P.B. et al.: "Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin and cyclophosphamide". Cancer, 1985, 56, 2756.

[18] Slayton R.E., Park R.C., Silverberg S.G., Shingleton H., Creasman W.T., Blessing J.A.: "Vincristine, dactinomycin and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group study (a final report)". Cancer, 1985, 56, 243.

[19] Peccatori F.,B onazzi C.,C hiari S.,L andoni F.,C olombo N.,M angioni C.: "Surgical management of malignant ovarian germ-cell tumors: 10 years'experience of 129 patients". Ohstet. Gynecol., 1995, 86 (3), 367.

[20] Buttram V.C. Jr.,V aqero C.: "Post-ovarian wedge resection adhesive disease". Fertil. Steril., I 975, 26, 874.

[21] Gershenson D.M.: "Management of early ovarian cancer: germ cell and sex cord-stromal tumors". Gynecol. Oncol., 1994, 55, S62.

[22] National Institutes of Health Consensus Developernent Panel on Ovarian Cancer: "NIH consensus conference. Ovarian cancer. Screening, treatment and follow-up". JAMA, 1995, 8, 491.

[23] Kanazawa K., Takaaki S., Sakumoto K.: "Treatment of malignant ovarian germ cell tumors with preservation of fertility. Reproductive performance after persistent remission". Am. J. Clin. Oncol., 2000, 23 (3), 244.

[24] Weibel M.A., Majno 0.: "Peritoneal adhesion and their relation to abdominal surgery: a post mortem study". Am. J. Surg., 1973, 126, 345.

[25] Oelsner 0., Menezer J., Insler V., Serr D.R.: "Fertility after ovanan surgery for benign tumor under the age of twenty". Int. J. Gynecol Obstet., 1975, 13, 145.

[26] Laios 0.: "Risk factors for tubal infertility among infertile and fertile women". Eur. J. Gyneco/. Reprod. Biol., 1988, 29, 129.

[27] Reimer R.R., Over R., F raumeni J.P., Young R.C.: "Acute leukemia after alkylating-agent therapy of ovarian cancer". N. Engl. J. Med., 1977, 297, 177.

[28] Greene M.H., Harris E.L., Gershenson D.M., Boice J.D., Malkasian G.D., Melton L.J. et al.: "Melphalan may be a more potent leukemogen than is cyclophosphamide". Ann. Intern. Med., 1986, 105, 360.

[29] De Wit, Stoter G., Kaye S.B. et al.: "The importance of bleomycin in combination chemotherapy for good prognosis testicular nonseminoma: A randomized study of the ORTC Genitourinary Tract Cancer Cooperative Group". J. Clin. Oneal., 1997, 15, 1837.

[30] Levi J.A., Raghavan D., Harvey V. et al.: "The importance of bleomycin in combination chemotherapy for good prognosis germ cell carcinoma". J. Clin. Oneal., 1993, 11, 1300.

[31] Chapman R.M., Sutellife S.B., Malpas J.S.: "Citotoxic induced ovarian failure in women with Hodgkin's disease. Hormone function". JAMA, 1979, 242, 1877.

[32] Schilky R.L., Lewis B.J., Sherins R.J., Young R.C.: "Gonadal dysfunction in patients receiving chemotherapy for cancer". Ann Intern. Med., 1980, 93, 109.

[33] Nicosia S.V., Matus-Ridley M., Meadows A.T.: "Gonadal effects of cancer therapy in girls". Cancer, 1985, 55, 2364

[34] Siris E.S., Leventhal B.G., Vaituka山s J.L.: "Effects of childwood leukemia and chemotherapy on puberty and reproductive function in girls". N. Engl. J. Med., 1976, 294, 1143.

[35] Chapman R.M., Ress L.H., Sutcliffe S.B. et al.: "Cyclical combination chemotherapy and gonadal function". Lancet, 1979, I, 285.

[36] Chapman R.M., Sutcliffe S.B.: "Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease". Blood, 1981, 58, 849.

[37] Ortin T.T., Shostak C.A., Donaldson S.S.: "Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience". Int. J. Radio/. Oncol. Biol. Phys., 1990, 19, 873.

[38] Kreuser E.D., Klingmuller D., Thiel E.:'The rule of LHRH-analogues in protecting gonadal functions during chemotherapy and irradiation". Eur. Urol., 1993, 23, 157.

[39] Pektasides D., Rustin G.J.S., N ewlands E.S., Begent R.H., Bagshawe K.D.: "Fertility after chemotherapy for ovarian germ cell tumors". Br. J. Obstet. Gynecol., 1987, 194, 477.

[40] Sessa C., Bonazzi C., Landoni F., Pecorelli S., Sartori E., Mangioni C.: "Cisplatin, vincristine, and bleomycin combination chemotherapy in endodermal sinus tumor of the ovary". Obstet. Gynecol., 1987, 70, 220.

[41] Gershenson D.M.: "Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors". J. C!in. Oncol., 1988, 6 (2), 270.

[42] Wu P.C., Huang R.L., Lang J.H., Huang H.F., Lian l.J., Tang M.Y.:"Treatment of malignant germ cell tumors with preservation of fertility: a report of 28 cases". Gynecol. Oncol., 1991, 40, 2.

[43] Perrin L.C., Low J., Nicklin J.L. et al.: "Fertility and ovarian function after conservative surgery for germ cell tumors of the ovary" Aust. N. Z. Obstet. Gynaecol., 1999, 39, 243.